Curative Effect of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in Stable Phase of COPD and the Impact on the Expression of Th17 Cells
DENG Bin
WANG Ding-yong
DENG Ying-guo
CAO Li
FENG Xia
Abstract：Objective To observe curative effect of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhala-tion in stable phase of chronic obstructive pulmonary disease ( COPD) and the impact on the expression of Th17 cells in the pe-ripheral serum. Methods 80 patients with definitely diagnosed COPD in stable phase during January 2011 to November 2012 were included in the study, and were randomly divided into the observation group (n=40) and the control group (n=40). At the end of the 2 years of follow-up, 7 patients discontinued Salmeterol Xinafoate medication and Fluticasone Propionate Powder for Inhalation and 4 cases lost follow-up in the control group as drop outs. Frequencies of acute exacerbations, pulmonary func-tion changes, changes in quality of life and the expressional changes of Th17 during the follow-up period of two groups were ob-served. Results (1) During the follow-up, the observation group had acute attack for (1. 8 ± 0. 3) times, the control group for (2. 4 ± 1. 9) times, and the differences showed statistical significance. (2)In the two groups with the first forced expiratory vol-ume (FEV1), FEV1/forced vital capacity (FVC), the quality of life SGRQ scores, percentage of CD4+IL-17+ T-cell, the differences before the treatment and after the treatment were statistically significant (P<0. 05), the downward tendency of the observation group was less than that of the control group (P<0. 05). The rise tendency of life quality SGRO scores was higher (P<0. 05). Conclusion Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation can slow down the progression of COPD, which may be associated with the down regulation of Th17 cell in the peripheral blood.
Keywords：Salmeterol assigned aerosol pulmonary diseaseChronic obstructiveTh17 cellTreatment result
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 88-91 )